Turkish Republic, Ministry of Health ‘Türkiye Hudut ve Sahiller Genel Müdürlüğü’ to acquire advanced cancer treatment systems from Elekta

Seven hospitals to acquire linear accelerators and sophisticated software for
radiation therapy
ISTANBUL, January 16 – Elekta (EKTA-B.ST) has received an order from the
Republic of Turkey’s Ministry of Health (Directorate General of Health for
Border and Coastal Areas (http://www.hssgm.gov.tr/EN/Default.aspx)) for
nine Elekta Synergy® (http://www.elekta.com/synergy) linear accelerators
(linacs), all including Agility™ (http://www.elekta.com/agility) multileaf
collimators for high-resolution beam shaping, as well as
Monaco® (http://www.elekta.com/monaco) 5.0 treatment planning system and
MOSAIQ® (http://www.elekta.com/mosaiq) oncology information system.

Elekta Synergy allows physicians to better visualize tumors while Agility
enables precise shaping of the radiation beam around the tumor. Using volumetric
modulated arc therapy (VMAT) technology facilitates rapid treatment time,
benefitting both the hospitals and patients.

According to the World Health Organization, almost 258 per 100,000 people in
Turkey are diagnosed with cancer each
year[1] (http://connect.ne.cision.com#_ftn1). Cancer is the second leading cause
of death in Turkey and the most common cancers for men and women are lung and
breast, respectively. Elekta Synergy has been clinically proven to be effective
in managing both types of cancer, as well as several other
indications.[2] (http://connect.ne.cision.com#_ftn2)
[3] (http://connect.ne.cision.com#_ftn3)

Ian Alexander, Executive Vice President of Elekta's Region Europe, Africa, Latin
America and Middle East, says: “We are delighted to provide the treatment
solutions that will allow the Turkish Ministry of Health to offer state-of-the
-art cancer care. We’re especially pleased that many of the hospitals are new
customers to Elekta.

“This is the first major deal procured by our new entity, Elekta Turkey, which
was developed through the recent acquisition of Mesi
Medikal (http://bit.ly/1ynxQ2O). We look forward to increased collaboration
between our unit and the country’s health care sector.”

Elekta was awarded the contract based on a public tender where price and
performance were the key criteria. The total value of the deal is almost EUR 16
million (approximately USD 18.5 million) and has been booked during Elekta’s
third quarter 2014/15.

----------------------------------------------------------------------

[1] (http://connect.ne.cision.com#_ftnref1) The International Agency for
Research on Cancer (IARC), GLOBOCAN
project (http://globocan.iarc.fr/Pages/fact_sheets_population.aspx)
[2] (http://connect.ne.cision.com#_ftnref2) Volumetric modulated arc therapy for
lung stereotactic radiation therapy can achieve high local control rates
Published online Nov 11, 2014. doi: 10.1186/s13014-014-0243
-1 (http://dx.doi.org/10.1186%2Fs13014-014-0243-1)
[3] (http://connect.ne.cision.com#_ftnref3) Single-Arc Volumetric Modulated Arc
Therapy Planning for Left Breast Cancer and Regional
Nodes (http://paperity.org/p/34538608/single-arc-volumetric-modulated-arc
-therapy-planning-for-left-breast-cancer-and-regional)
Journal of Radiation Research, Jan 2012

# # #

For further information, please contact:
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on January 16, 2015.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.